Now showing items 21-40 of 46

    • Low expression levels of ATM may substitute for CHEK2 / TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer 

      Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein (Peer reviewed; Journal article, 2012-03-15)
      Introduction: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNAdamaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and ...
    • MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk 

      Gansmo, Liv Beathe; Bjørnslett, Merete Pauline; Halle, Mari Kyllesø; Salvesen, Helga; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Dørum, Anne; Lønning, Per Eystein; Knappskog, Stian (Peer reviewed; Journal article, 2017-02-03)
      Background: The del1518 (rs3730485) polymorphism is an in/del variant in the MDM2 promoter P1. The variant is in complete linkage disequilibrium with MDM2 SNP309 (rs2279744) and has previously been found associated with ...
    • MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk 

      Knappskog, Stian; Gansmo, Liv B.; Romundstad, Pål; Bjørnslett, Merete; Trovik, Jone; Lønning, Per Eystein; Salvesen, Helga Birgitte (Peer reviewed; Journal article, 2012-04-30)
      The MDM2 proto-oncogene plays a key role in central cellular processes like growth control and apoptosis, and the gene locus is frequently amplified in sarcomas. Two polymorphisms located in the MDM2 promoter P2 have been ...
    • MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer 

      Helwa, Reham; Gansmo, Liv Beathe; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Ryan, Bríd M.; Harris, Curtis C.; Lønning, Per Eystein; Knappskog, Stian (Peer reviewed; Journal article, 2016-09-14)
      Two functional SNPs (SNP285G > C; rs117039649 and SNP309T > G; rs2279744) have previously been reported to modulate Sp1 transcription factor binding to the promoter of the proto-oncogene MDM2, and to influence cancer risk. ...
    • MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung- and prostate cancer risk. 

      Gansmo, Liv Beathe; Romundstad, Pål Richard; Birkeland, Einar Elvbakken; Hveem, Kristian; Vatten, Lars Johan; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2015-10-16)
      The MDM4 protein plays an important part in the negative regulation of the tumor suppressor p53 through its interaction with MDM2. In line with this, MDM4 amplification has been observed in several tumor forms. A polymorphism ...
    • The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer 

      Gansmo, Liv Beathe; Bjørnslett, Merete Pauline; Halle, Mari Kyllesø; Salvesen, Helga Birgitte; Dørum, Anne; Birkeland, Einar Elvbakken; Hveem, Kristian; Romundstad, Pål Richard; Vatten, Lars Johan; Lønning, Per Eystein; Knappskog, Stian (Peer reviewed; Journal article, 2016-02-11)
      The MDM4 protein (also known as MDMX or HDMX) is a negative regulator of p53, not only by direct interaction but also through its interaction with MDM2. Further, MDM4 overexpression and amplification have been observed in ...
    • Multilocus analysis of SNP and metabolic data within a given pathway 

      Kristensen, Vessela N.; Tsalenko, Anya; Geisler, Jürgen; Faldaas, Anne; Grenaker, Grethe Irene; Lingjærde, Ole Christian; Fjeldstad, Ståle; Yakhini, Zohar; Lønning, Per Eystein; Børresen-Dale, Anne-Lise (BMC Genomics 7(5), Peer reviewed; Journal article, 2006-01-13)
      Background: Complex traits, which are under the influence of multiple and possibly interacting genes, have become a subject of new statistical methodological research. One of the greatest challenges facing human geneticists ...
    • The multitude of molecular analyses in cancer: the opening of Pandora’s box 

      Russnes, Hege Elisabeth Giercksky; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Lingjærde, Ole Christian (Peer reviewed; Journal article, 2014-09-03)
      The availability of large amounts of molecular data of unprecedented depth and width has instigated new paths of interdisciplinary activity in cancer research. Translation of such information to allow its optimal use in ...
    • MYC-induced miR-203b-3p and miR-203a-3p control Bcl-xL expression and paclitaxel sensitivity in tumor cells 

      Aakko, Sofia; Straume, Anne Hege; Birkeland, Einar Elvbakken; Chen, Ping; Qiao, Xi; Lønning, Per Eystein; Kallio, Marko J. (Peer reviewed; Journal article, 2018)
      Taxanes are chemotherapeutic agents used in the treatment of solid tumors, particularly of breast, ovarian, and lung origin. However, patients show divergent therapy responses, and the molecular determinants of taxane ...
    • The novel microRNAs hsa-miR-nov7 and hsamiR- nov3 are over-expressed in locally advanced breast cancer 

      Poduval, Deepak; Sichmanovà, Zuzana; Straume, Anne Hege; Lønning, Per Eystein; Knappskog, Stian (Journal article; Peer reviewed, 2020)
      miRNAs are an important class of small non-coding RNAs, which play a versatile role in gene regulation at the post-transcriptional level. Expression of miRNAs is often deregulated in human cancers. We analyzed small RNA ...
    • NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients 

      Borgen, Elin; Rypdal, Maria Christine; Sosa, Maria Soledad; Renolen, Anne; Schlichting, Ellen; Lønning, Per Eystein; Synnestvedt, Marit; Aguirre-Ghiso, Julio; Naume, Bjørn (Peer reviewed; Journal article, 2018-10-16)
      Background: The presence of disseminated tumor cells (DTCs) in bone marrow (BM) is an independent prognostic factor in early breast cancer but does not uniformly predict outcome. Tumor cells can persist in a quiescent state ...
    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Journal article; Peer reviewed, 2020)
      Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ...
    • The optimal cut-off values for tumor size, number of lesions, and CEA levels in patients with surgically treated colorectal cancer liver metastases: An international, multi-institutional study 

      Kamphues, Carsten; Andreatos, Nikolaos; Kruppa, Jochen; Buettner, Stefan; Wang, Jaeyun; Sasaki, Kazunari; Wagner, Doris; Morioka, Daisuke; Fitschek, Fabian; Løes, Inger Marie; Imai, Katsunori; Sun, Jinger; Poultsides, George; Kaczirek, Klaus; Lønning, Per Eystein; Endo, Itaru; Baba, Hideo; Kornprat, Peter; Aucejo, Federico N.; Wolfgang, Christopher L.; Kreis, Martin E.; Weiss, Matthew J.; Margonis, Georgios Antonios (Journal article; Peer reviewed, 2021)
      Background and Objectives Despite the long-standing consensus on the importance of tumor size, tumor number and carcinoembryonic antigen (CEA) levels as predictors of long-term outcomes among patients with colorectal liver ...
    • Patterns of genomic evolution in advanced melanoma 

      Birkeland, Einar Elvbakken; Zhang, Shan; Poduval, Deepak; Geisler, Jürgen; Nakken, Sigve; Vodak, Daniel; Meza, Leonardo Zepeda; Hovig, Eivind; Myklebost, Ola; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2018-07-10)
      Genomic alterations occurring during melanoma progression and the resulting genomic heterogeneity between metastatic deposits remain incompletely understood. Analyzing 86 metastatic melanoma deposits from 53 patients with ...
    • Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimen 

      Løes, Inger Marie; Immervoll, Heike; Angelsen, Jon-Helge; Horn, Arild; Geisler, Jürgen; Busch, Christian; Lønning, Per Eystein; Knappskog, Stian (Peer reviewed; Journal article, 2015-02)
      Personalized cancer care requires reliable biomarkers. While the BRAF V600E mutation is implemented in the clinic, no method for its detection has so far been established as reference. We aimed to perform a comprehensive ...
    • Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival 

      Mathiesen, Randi Margit Ruud; Borgen, Elin; Renolen, Anne; Løkkevik, Erik; Nesland, Jahn M.; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Kvalheim, Gunnar; Lønning, Per Eystein; Naume, Bjørn (Peer reviewed; Journal article, 2012-08-14)
      Introduction: Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine ...
    • Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis 

      Gansmo, Liv Beathe; Lie, Benedicte Alexandra; Mæhlen, Marthe Thoresen; Vatten, Lars Johan; Romundstad, Pål Richard; Hveem, Kristian; Lønning, Per Eystein; Knappskog, Stian (Journal article; Peer reviewed, 2021)
      Background In addition to being a tumour suppressor, TP53 is a suppressor of inflammation, and dysfunction of this gene has been related to autoimmune diseases. Patients with autoimmunity, such as rheumatoid arthritis ...
    • Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649) 

      Knappskog, Stian; Gansmo, Liv Beathe; Dibirova, Khadizha; Metspalu, Andres; Cybulski, Cezary; Peterlongo, Paolo; Aaltonen, Lauri; Vatten, Lars Johan; Romundstad, Pål Richard; Hveem, Kristian; Devilee, Peter; Evans, Gareth D; Lin, Dongxin; Van Camp, Guy; Manolopoulos, Vangelis G; Osorio, Ana; Milani, Lili; Ozcelik, Tayfun; Zalloua, Pierre; Mouzaya, Francis; Bliznetz, Elena; Balanovska, Elena; Pocheshkova, Elvira; Kucinskas, Vaidutis; Atramentova, Lubov; Nymadawa, Pagbajabyn; Titov, Konstantin; Lavryashina, Maria; Yusupov, Yuldash; Bogdanova, Natalia; Koshel, Sergey; Zamora, Jorge; Wedge, David C.; Charlesworth, Deborah; Dörk, Thilo; Balanovsky, Oleg; Lønning, Per Eystein (Peer reviewed; Journal article, 2014-04-18)
      The MDM2 promoter SNP285C is located on the SNP309G allele. While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and ...
    • Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel 

      Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjösne, Hans E.; Nysted, Arne; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, 2011-04-27)
      Background: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may ...
    • Prevalence of the CHEK2 R95* germline mutation 

      Knappskog, Stian; Leirvaag, Beryl; Gansmo, Liv Beate; Romundstad, Pål; Hveem, Kristian; Vatten, Lars; Lønning, Per Eystein (Peer reviewed; Journal article, 2016-09-27)
      Background: While germline CHEK2 mutations have been linked to a moderately elevated cancer risk, to date, a limited number of such mutations have been identified. Recently, we reported a germline nonsense mutation (C283T; ...